KeraStat® Cream
Radiation Dermatitis Management
Key Facts
About KeraNetics
KeraNetics is a private, commercial-stage biotech company specializing in regenerative medicine through its proprietary keratin-based biomaterial platform. The company's flagship product, KeraStat® Cream, is FDA-cleared and commercially available for the management of radiation dermatitis, a severe skin condition affecting cancer patients undergoing radiotherapy. With a foundation rooted in research from the Wake Forest Institute for Regenerative Medicine and initial goals to treat battlefield injuries, KeraNetics has successfully translated its platform into a marketed product with additional development programs in wound care. The company has secured government contracts and established a pharmacy distribution network to support its commercial growth.
View full company profileAbout KeraNetics
KeraNetics is a private, commercial-stage biotech company specializing in regenerative medicine through its proprietary keratin-based biomaterial platform. The company's flagship product, KeraStat® Cream, is FDA-cleared and commercially available for the management of radiation dermatitis, a severe skin condition affecting cancer patients undergoing radiotherapy. With a foundation rooted in research from the Wake Forest Institute for Regenerative Medicine and initial goals to treat battlefield injuries, KeraNetics has successfully translated its platform into a marketed product with additional development programs in wound care. The company has secured government contracts and established a pharmacy distribution network to support its commercial growth.
View full company profileAbout KeraNetics
KeraNetics is a private, commercial-stage biotech company specializing in regenerative medicine through its proprietary keratin-based biomaterial platform. The company's flagship product, KeraStat® Cream, is FDA-cleared and commercially available for the management of radiation dermatitis, a severe skin condition affecting cancer patients undergoing radiotherapy. With a foundation rooted in research from the Wake Forest Institute for Regenerative Medicine and initial goals to treat battlefield injuries, KeraNetics has successfully translated its platform into a marketed product with additional development programs in wound care. The company has secured government contracts and established a pharmacy distribution network to support its commercial growth.
View full company profile